[1]刚 怡.基于Th1/Th2免疫平衡探讨血栓通胶囊对视网膜静脉阻塞的疗效及机制[J].陕西中医,2022,(7):906-909.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.022]
　GANG Yi.Effect and mechanism of Xueshuantong capsule on patients with retinal vein occlusion via Th1/Th2[J].,2022,(7):906-909.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.022]
点击复制

基于Th1/Th2免疫平衡探讨血栓通胶囊对视网膜静脉阻塞的疗效及机制
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年7期
页码:
906-909
栏目:
临床研究
出版日期:
2022-07-05

文章信息/Info

Title:
Effect and mechanism of Xueshuantong capsule on patients with retinal vein occlusion via Th1/Th2
作者:
刚 怡
(齐齐哈尔市中医院,黑龙江 齐齐哈尔 161006)
Author(s):
GANG Yi
(Qiqihar Traditional Chinese Medicine Hospital,Qiqihar 161006,China)
关键词:
视网膜静脉阻塞;  血栓通胶囊;  抗VEGF治疗;  毛细血管灌注面积;  Th1/Th2平衡
Keywords:
Retinal vein occlusion;  Xueshuantong capsule;  Anti VEGF therapy;  Capillary perfusion area;  Th1/Th2 balance
分类号:
R 774.1
DOI:
DOI:10.3969/j.issn.1000-7369.2022.07.022
文献标志码:
A
摘要:
目的:探究血栓通胶囊对视网膜静脉阻塞(RVO)患者的治疗效果与作用机制。方法:回顾性选取84例RVO患者作为研究对象,依据治疗方案的不同分为对照组(n=42)与观察组(n=42),对照组采用常规抗血管内皮生长因子(VEGF)治疗,观察组则在对照组基础上给予血栓通胶囊治疗。对比两组患者治疗前后的黄斑中央视网膜厚度(CRT)、视力水平、眼部血流灌注面积、中医症状积分、免疫功能、综合疗效以及用药安全性。结果:治疗后1、3个月,观察组CRT小于对照组(P<0.05); 治疗后1、3个月,观察组最佳矫正视力明显高于对照组(P<0.05); 治疗后3个月,观察组视网膜浅层毛细血管区血流密度(SCP)、深层毛细血管区血流密度(DCP)面积明显增大(P<0.05),中心凹无血管区面积(FAZ)明显缩小(P<0.05),与对照组比较差异有统计学意义(P<0.05)。治疗后1、3个月,观察组中医症状积分明显低于对照组(P<0.05); 观察组治疗,总有效率明显高于对照组(P<0.05)。治疗后,观察组IgA、IgM、IgG、Th1/Th2水平均高于对照组(P<0.05)。两组患者在治疗过程中均无不良反应及不良事件发生。结论:血栓通胶囊治疗RVO疗效显著,其机制可能与调节Th1/Th2平衡有关。
Abstract:
Objective:To explore the therapeutic effect and mechanism of Xueshuantong capsule in patients with retinal vein occlusion(RVO).Methods:84 patients with RVO were retrospectively selected as the research objects.According to different treatment schemes,they were divided into control group(n=42)and observation group(n=42).The control group was treated with routine anti VEGF treatment,while the observation group was treated with Xueshuantong capsule on the basis of the control group.The central macular retina thickness(CRT),visual acuity level,eye blood perfusion area,TCM symptom score,immune function,comprehensive efficacy and medication safety were compared between the two groups before and after treatment.Results:At one and three months after treatment,the CRT index of the observation group was lower than that of the control group(P<0.05).At one and three months after treatment,the best corrected visual acuity in the observation group was significantly higher than that in the control group(P<0.05).Three months after treatment,the area of SCP and DCP in the observation group increased significantly(P<0.05),while FAZ decreased significantly(P<0.05),and the difference was statistically significant compared with the control group(P<0.05).At one and three months after treatment,the TCM symptom score of the observation group was significantly lower than that of the control group(P<0.05).The effective rate of observation group was significantly higher than that of control group(P<0.05).After treatment,the levels of IgA,IgM,IgG and Th1/Th2 in observation group were higher than those in control group(P<0.05).There were no adverse reactions and adverse events in two groups during treatment.Conclusion:Xueshuantong capsule has a significant therapeutic effect on RVO,and its mechanism may be related to the regulation of Th1/Th2 balance.

参考文献/References:

[1] 韩中舒,余锦强.视网膜静脉阻塞所致黄斑水肿的治疗进展[J].实用临床医药杂志,2020,24(16):122-128.
[2] 李玲娜,董志军.视网膜静脉阻塞的研究进展[J].国际眼科杂志,2020,20(8):1371-1374.
[3] 谢立科.中西医诊治视网膜静脉阻塞之管窥[J].中国中医眼科杂志,2020,30(5):303-307.
[4] 吴 豪,王 菁,陈 茜,等.中药联合抗VEGF药物治疗视网膜静脉阻塞性黄斑水肿的疗效观察[J].时珍国医国药,2020,31(1):117-120.
[5] 刘自强,孟 欢,农璐琪,等.中西医结合治疗视网膜静脉阻塞继发黄斑水肿的Meta分析[J].海南医学院学报,2020,26(17):1315-1322.
[6] 孙 岩,马健萍,徐茂生,等.复方血栓通滴丸治疗视网膜静脉阻塞的临床安全性与有效性观察[J].辽宁中医杂志,2020,47(3):133-136,222.
[7] 张 正,李银花.激光联合复方血栓通胶囊降低视网膜静脉阻塞患者黄斑中心凹厚度的效果观察[J].医学理论与实践,2019,32(18):2953-2954.
[8] 吴虎强,保明瑶,杨晓霞,等.基于“血水同源”理论探讨视网膜静脉阻塞的防治[J].中国中医急症,2022,31(4):727-729.
[9] 丁雪菲,李秋明,杨 鸽,等.抗VEGF治疗不同类型视网膜静脉阻塞继发黄斑水肿的效果[J].中华眼外伤职业眼病杂志,2022,44(3):161-165.
[10] 金 琪,郝晓凤,谢立科,等.基于络脉理论探讨视网膜静脉阻塞微循环的变化[J].中国中医眼科杂志,2022,32(2):127-130.
[11] 张 宏,高作书,史 强,等.复方血栓通滴丸治疗视网膜静脉阻塞的多中心随机盲法对照研究[J].中国处方药,2019,17(6):119-120.
[12] 陈博文.玻璃体腔内注射雷珠单抗治疗视网膜静脉阻塞合并黄斑水肿的效果与安全性[J].临床医学研究与实践,2022,7(16):122-124.
[13] 王秀春.复方血栓通胶囊联合激光光凝术治疗视网膜分支静脉阻塞疗效分析[J].血管与腔内血管外科杂志,2019,5(1):57-60,73.
[14] 何茂秋,董 玉.视网膜静脉阻塞的中西医治疗进展[J].云南中医中药杂志,2018,39(10):70-72.
[15] 马宏杰,王家良.复方血栓通胶囊治疗视网膜静脉阻塞继发黄斑水肿及对眼血流动力学的影响[J].吉林中医药,2018,38(9):1042-1046.
[16] 白云潇.中西医结合治疗视网膜静脉阻塞疗效分析[J].实用中医药杂志,2017,33(7):778.
[17] 苏汉权,张远航,江志华,等.复方血栓通胶囊治疗视网膜静脉阻塞的疗效[J].中国处方药,2019,17(1):71-72.
[18] 董洁泓,梁锋锋.探析血栓通与复方樟柳碱联合在视网膜静脉阻塞治疗中的临床效果[J].齐齐哈尔医学院学报,2017,38(12):1436-1437.
[19] 孙 建,刘新宇.三七总皂苷胶囊治疗糖尿病周围神经病变临床疗效及机制研究[J].陕西医学杂志,2020,49(11):1496-1498,1506.
[20] 高东阳.血栓通胶囊联合注射用血塞通对老年脑梗死患者的影响[J].中外医学研究,2022,20(2):25-28.
[21] 宋玫侠,李 上.复方血栓通胶囊治疗视网膜静脉阻塞临床疗效观察[J].基层医学论坛,2017,21(1):66-67.
[22] 王 宇,孔德宁.针刺配合复方血栓通治疗视网膜静脉阻塞的临床疗效及对外周血VEGF及ET-1表达的影响[J].上海针灸杂志,2019,38(8):883-887.
[23] 林 静,黄珍珍.阿司匹林联合复方血栓通胶囊治疗高血压性视网膜病变的效果[J].慢性病学杂志,2021,22(12):1934-1936,1940.
[24] 安 娜,黄志鹏,游必凯,等.视网膜激光光凝术联合复方血栓通胶囊治疗眼底病患者的疗效[J].实用医技杂志,2021,28(11):1348-1350.
[25] 张锡萍,张斐雪,郑书林,等.血栓通联合吡拉西坦对缺血性脑卒中患者中医证候评分、神经功能及血清NPY、Hcy水平的影响[J].陕西中医,2021,42(3):326-329.
[26] 王满华,袁铭悦.血栓通胶囊联合玻璃体腔注射康柏西普治疗增生性糖尿病视网膜病变的疗效观察[J].山西医药杂志,2021,50(18):2659-2661.
[27] 邢敏艳,严展军.血栓通联合尿激酶治疗视网膜动脉阻塞的临床效果观察[J].陕西医学杂志,2017,46(8):1138-1139.

更新日期/Last Update: 2022-07-07